Official UK procurement notice
Compounded mAbs - Cancer Therapies
Authority: Berkshire Healthcare NHS Foundation Trust (Central government)
What is being bought2 lots · detail below
Published requirement descriptionPhamacy Procurement Contract - A ranked framework for the supply and delivery of Compounded Monoclonal Antibodies (mAbs) for Intravenous Infusion for Chemotherapy indications split into 2 lots:
Lot 1: High Volume Products - 5 molecules / all brands
Lot 2: Lower Volume Products - 13 molecules / all brands
The ranked framework will be open to the participating Trusts of the South East Pharmacy Procurement Service (SEPPS):
Thames Valley and Wessex (TV&W)
- Buckinghamshire Healthcare NHS Trust
- Frimley Health NHS Foundation Trust
- Hampshire Hospitals NHS Foundation Trust
- Isle of Wight NHS Trust
- Hampshire and Isle of Wight Healthcare NHS Foundation Trust
- Milton Keynes University Hospital NHS Foundation Trust
- Oxford Health NHS Foundation Trust
- Oxford University Hospitals NHS Foundation Trust
- Portsmouth Hospitals NHS Trust
- Royal Berkshire NHS Foundation Trust
- University Hospital Southampton NHS Foundation Trust
South-East Coast (SEC)
- Ashford and St. Peters’ Hospitals NHS Foundation Trust
- Dartford and Gravesham NHS Trust
- East Kent Hospitals University NHS Foundation Trust
- East Sussex Healthcare NHS Trust
- Kent Community Health NHS Trust
- Maidstone & Tunbridge Wells NHS Trust
- Medway NHS Foundation Trust
- Queen Victoria Hospitals NHS Foundation Trust
- Royal Surrey County Hospital NHS Foundation Trust
- Surrey and Borders Partnership NHS Foundation Trust
- Surrey and Sussex Healthcare NHS Trust
- Sussex Community NHS Trust
- Sussex Partnership NHS Foundation Trust
- University Hospitals Sussex NHS Foundation Trust
- Berkshire Healthcare NHS Foundation Trust
This framework will be available for use by Trusts in East of England and London regions, but the volumes for these regions have not been included for adjudication as part of the tender process.
SEC Trusts can utilise this tender for products or services not covered by the National unlicensed aseptically prepared cytotoxic medicines and mAbs framework via MPSC.
Please note: we did not publish a preliminary market engagement notice (UK2) for the following reasons:
- we are not seeking to further develop our requirements or procurement approach.
- we have procured similar supply arrangements via the Open procedure and deployed similar conditions of participation and award criteria. These have yielded good results previously.
- we have already prepared our tender pack (see attached), that detail standard NHS contractual terms which have been found to be acceptable to the supply chain.
- we understand the likely suppliers who will be interested but the open notice approach gives opportunity to others looking to enter the mAbs supply market
- The authority expects to re-tender this requirement around 2 Jul 2029, 23:59 BST.
CPV: Pharmaceutical products · Pharmacy services
How this framework works
From the published notice- Type
- Open framework
- Call-offs
- call-offs are awarded directly to appointed suppliers, without further competition
- Framework period
- 2 yrs · up to 4 yrs from 1 Dec 2026
Who may buy through it
The ranked framework will be open to the participating Trusts of the South East Pharmacy Procurement Service (SEPPS). See Contract Description.
Published description of the framework
The Contracting Authorities reserve the right to maintain supply with the incumbent Supplier to maintain continuity of care for patients.
Framework call-off rules require the highest ranked Supplier for each LOT will be approached first to provide Services. Only should the highest ranked Supplier not be able to meet the demand and provide an acceptable product, will the next highest ranked Supplier be approached.
Lots and requirements (2)Procurement structure
2 lots · all with a published value · same conditions of participation on every lot · same evaluation weights on every lotLot #1High Volume Products - 5 molecules / all brandsRenewalPublished value£170,640,000
- Economic & financial standing
See Tender Pack
- Technical & professional ability
See Tender Pack
Lot #2Lower Volume Products - 13 molecules / all brandsRenewalPublished value£45,360,000
- Economic & financial standing
See Tender Pack
- Technical & professional ability
See Tender Pack
What it takes to wini
How this buyer will score bids.
The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).
Evaluation split and conditions of participation as published; the tender pack may add morei
How this buyer will score bids.
The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).
Published sub-criteria (6)
- Procurement Specific Questionnaire: 0.01%
- Framework Agreement T&Cs Acceptance: 0.01%
- Technical Compliance/ Technical Capability/ Quality Assurance (40%): 39.98%
- Shelf Life (15%): 15%
- Price (35%): 35%
- Social Value (10%): 10%
Published award criteria (6)
- Procurement Specific Questionnaire: Pass/Fail - see Tender Pack - ITT Instructions for detail
- Framework Agreement T&Cs Acceptance: Pass/Fail - see Tender Pack - ITT Instructions for detail
- Technical Compliance/ Technical Capability/ Quality Assurance (40%): Technical Compliance / Technical Capability/ Quality Assurance. Responses to Technical Questions - see Tender Pack - ITT Instructions for detail. Note: MHRA Licensing is Pass/Fail
- Social Value (10%): Responses to Social Value Questions - see Tender Pack - ITT Instructions for detail.
- Shelf Life (15%): Shelf Life Assessment - see Tender Pack - ITT Instructions for detail
- Price (35%): Assessment of Pricing Model - see Tender Pack - ITT Instructions for detail
- Economic & financial standing
See Tender Pack
- Technical & professional ability
See Tender Pack
- Price carries 35 of 100 points: a 10% discount moves about 3.5 points. The method statement decides this lot, not the discount.
- “Compounded mAbs - Cancer Therapies” is a framework: the contest is a place on its panel, not a single contract, and call-offs are awarded directly: getting appointed is the whole game.
Price arithmetic assumes straight proportional scoring; the tender pack may use another formula.
Procedure terms & legal framework
From the official record- Procedure method
- Open procedure
- Legal basis
- UKPGA · 2023/54 Procurement Act 2023
- Procurement category
- Services
- Notice status
- Closed
- Procurement threshold
- Above threshold (FTS publication)
- Regulatory regime
- Standard
- Commercial structure
- Framework agreement
- Who may use this agreement
- The ranked framework will be open to the participating Trusts of the South East Pharmacy Procurement Service (SEPPS). See Contract Description.
- Competition type
- Competitive procedure
- GPA / WTO covered
- Unspecified in notice
- Recurring procurement
- Yes · next expected 2 Jul 2029
- First published
- 7 May 2026, 16:42 BST
- Last source update
- 12 May 2026, 09:47 BST
- Award evaluation window
- Submission end – 16 Nov 2026
- Authority reference
PR BHFT 0715- FTS notice number
2026/S 000-042148- Latest notice
- Tender notice (UK4)
- Classification (CPV)
- Delivery area
- Official registry OCID
ocds-h6vhtk-0693deFind a Tender- Contract terms summary
30 day payment terms as set out in the Tender Pack - see 'PR BHFT 0715 - ITT Open - Schedule 7 - Draft Contract'.
- Risks
The following have been identified as ‘Known Risks’:
Denial of access to raw material medicines to Suppliers, which increases the cost of mAb compounds, dose bands or brands on the Framework Agreement. Where this can be demonstrated by the Supplier, the Price for affected mAbs will be agreed and the Framework Prices modified as a Variation which may result in the overall Framework Agreement value increasing.
How it was run
Official notice- Appointment period ends
- 22 Jun 2026, 12:00 BST
- Clarification deadline
- 16 Jun 2026, 12:00 BST
- Submission channel
- Official e-sourcing portal
- Electronic submission
- Allowed
- Accepted languages
- en
Timeline
7 May 2026 → 1 Dec 2026 · 6 dates- Tender notice published173 days ago7 May 2026, 16:42 BST
- Latest notice published168 days ago12 May 2026, 09:47 BST
- Clarification questions by133 days ago16 Jun 2026, 12:00 BST
- Admission / appointment period ends127 days ago · period end, not a bid countdown22 Jun 2026, 12:00 BST
- Today27 Oct 2026
- Award decision expected byin 20 days16 Nov 2026, 23:59 GMT
- Contract startsin 34 days1 Dec 2026
Notice history
3 events · 2 releases on Find a Tender · since 7 May 2026- Tender notice published7 May 2026, 16:42 BSTUK4
- Tender notice published12 May 2026, 09:47 BSTUK4
- Deadline moved to 22 Jun 2026, 12:00 BST12 May 2026, 09:47 BST+14 days · was 8 Jun 2026, 12:15 BST
Published amendments (1)
Change to tender period resulting in the following alteration: Enquiry deadline change to 16/06/2026, 12.00pm Tender submission deadline change to 22/06/26, 12.00pm
Contracting authority & participating public bodies
Official documents & specifications (3)
Official links; attachments are not copiedTender pack and attachments
Notices published for this procedure
- Tender notice Tender notice on Find a Tender
- Tender notice Tender notice on Find a Tender